| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Biological Activity | |
| Product Type | |
| Shipping | |
| Species | |
| Storage |
Scientific Background
hERG (human ether-a-go-go-related gene) encodes the alpha subunit of a potassium ion channel, Kv11.1. It contains six transmembrane α-helices with a re-entrant "poreloop" between the fifth and the sixth transmembrane helices. This ion channel is best known for its contribution to the electrical activity of the heart that coordinates the heart's beating. When this channel's ability to conduct electrical current across the cell membrane is inhibited or compromised, either by application of drugs or by rare mutations, it can result in a potentially fatal disorder called long QT syndrome. A number of clinically successful drugs in the market exhibit the potential to inhibit hERG, and create a concomitant risk of sudden death as a side-effect, which has made hERG inhibition an important off-target that must be avoided during drug development.
Product Description
Ion ChannelHuman ERG channel has been stably expressed in HEK293 cell line and its expression was confirmed by Western blotting. The channel activity of hERG was characterized by a fluorescence-based assay using thallium influx as a surrogate indicator of potassium ion channel activity coupled with a thallium-sensitive fluorescent dye. When hERG-HEK293 cells were pre-loaded with thallium-sensitive dye and stimulated with stimulus buffer containing potassium/thallium, thallium ions flowed through the open hERG channels into the cells and bound the dye, generating a fluorescent signal. The hERG channel activity in hERG-HEK293 cells was blocked by hERG channel blockers, cisapride or dofetilide, causing the fluorescent signal triggered by thallium influx to drop to the basal level.
Product Specifications
| Host Cell Line | HEK293 |
|---|---|
| Host Species | Human |
| Transfection Method | Lipofectamine 2000 |
| Format | Aqueous solution containing DMSO |
| Supplied As | Each vial contains ~1.5 X 106 cells in 1 ml of 10% DMSO |
| Harmonized Tariff Code | 3002-5900 |
Quality Control & Validation
✓ Mycoplasma-TestedThe cell line has been screened using the PCR-based Venor™GeM Mycoplasma Detection kit (Sigma-Aldrich) to confirm the absence of Mycoplasma species.
Usage Notes
See data sheet for detailed culturing and assay protocol.
Regulatory Information
License Disclosure
Related Products
Related Products: Cat. #60187-1, 79531, 60187
Required Accessories: Cat. #79531,60187
This product is engineered on a HEK293 background (Human origin). The HEK293 host was selected for its compatibility with stable transfection and the target pathway or assay type. Consult the product datasheet for passage number guidance and recommended culture media.
This product is classified as BSL-2. Work must be performed in a certified BSL-2 laboratory by trained personnel. All procedures that may generate aerosols must be conducted inside a Class II Biological Safety Cabinet. Institutional Biosafety Committee (IBC) approval is required before use.
Yes. The cell line has been screened using the PCR-based Venor™GeM Mycoplasma Detection kit (Sigma-Aldrich) to confirm the absence of Mycoplasma species. We recommend that you independently confirm mycoplasma-negative status after receipt and periodically during routine culture using a validated detection kit.
Store this product at Liquid Nitrogen. Specifically: Immediately upon receipt, store vials in liquid nitrogen. Transfer cells from dry-ice shipping to the recommended storage immediately upon receipt. Avoid repeated freeze-thaw cycles, which reduce viability and may alter expression characteristics.
Yes, a license is required (Yes). Purchase of this cell line grants a time-limited research-use license for use in your immediate laboratory only. This license does not permit redistribution, sub-licensing, transfer to other institutions, or commercial use. Refer to the License Disclosure section on this page or contact BPS Bioscience for details regarding modifications or commercial licensing.
This stable cell line was generated using Lipofectamine 2000 for transgene delivery into the parental host. The stably integrated cells were selected using the appropriate resistance marker and verified for expression prior to cryopreservation.
Can't find the cell line you need—or require a custom engineered model for your study? We offer end-to-end support for diverse research needs, including:
- Cell line sourcing and selection (species, tissue, and disease model matching)
- Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA)
- Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs)
- Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles)
- Inducible expression systems (Tet-On/Off and regulatable constructs)
- Drug resistance marker selection (puromycin, G418, hygromycin, and others)
- Custom growth and media optimisation for specific assay requirements
- Scale-up production for high-throughput screening campaigns
- Authentication and QC services (STR profiling, mycoplasma testing, viability assessment)
Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
- Beacham, D.W. et al. (2010). J. Biomol. Screen. 15(4):441-446 2. Murphy, S.M. et al. (2006) J. Pharmacol. Toxicol. Methods. 54(1):42-55
